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Abstract
Active efflux pump is a primary fluoroquinolone resistant mechanism of clinical isolates of Salmonella enterica serovar
Typhimurium. RamA is an essential element in producing multidrug resistant (MDR) S.enterica serovar Typhimurium. The
aim of the present study was to elucidate the roles of RamA on the development of ciprofloxacin, the first choice for the
treatment of salmonellosis, resistance in S. enterica serovar Typhimurium. Spontaneous mutants were selected via several
passages of S. enterica serovar Typhimurium CVCC541 susceptible strain (ST) on M-H agar with increasing concentrations of
ciprofloxacin (CIP). Accumulation of ciprofloxacin was tested by the modified fluorometric method. The expression levels of
MDR efflux pumps were determined by real time RT-PCR. In ST and its spontaneous mutants, the ramA gene was inactivated
by insertion of the kan gene and compensated on a recombinant plasmid pGEXW(gst-ramA). The mutant prevention
concentration (MPC) and mutant frequencies of ciprofloxacin against ST and a spontaneous mutant in the presence,
absence and overexpression of RamA were tested. Four spontaneous mutants (SI1-SI4) were obtained. The SI1 (CIP MICs,
0.1 mg/L) without any target site mutation in its quinolone resistant determining regions (QRDRs) and SI3 (CIP MICs, 16 mg/
L) harboring the Ser83RPhe mutation in its QRDR of GyrA strains exhibited reduced susceptibility and resistance to
multidrugs, respectively. In SI1, RamA was the main factor that controlled the susceptibility to ciprofloxacin by activating
MdtK as well as increasing the expression level of acrAB. In SI3, RamA played predominant role in ciprofloxacin resistance via
increasing the expression level of acrAB. Likewise, the deficiency of RamA decreased the MPCs and mutant frequencies of ST
and SI2 to ciprofloxacin. In conclusion, the expression of RamA promoted the development of ciprofloxacin resistant
mutants of S. enterica serovar Typhimurium. The inhibition of RamA could decrease the appearance of the ciprofloxacin
resistant mutants.
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Introduction
Salmonella enterica serovar Typhimurium is considered as the
main food-borne pathogen responsible for causing human disease
[1]. Fluoroquinolones are the main drugs for the treatment of
salmonellosis. However, the emergence of multidrug resistance
(MDR) S. enterica serovar Typhimurium has led to the failure of the
treatment [2,3].
The resistant mechanisms of S. enterica serovar Typhimurium to
fluoroquinolone mainly include target site mutations in quinolone
resistant determining regions (QRDRs), decreased fluoroquinolone
uptake and plasmid-mediated fluoroquinolone resistance [4–6]. Target
site mutations in the QRDR of GyrA are very common and the
mutations occur most frequently at codons Ser 83 and Asp 87. A single
point mutation in the QRDR of GyrA can mediate high-level
resistance to nalidixic acid and reduce susceptibility to fluoroquino-
lones. The GyrB mutations that have been identified are mostly located
outside of the QRDR. The ParC mutations always occurred with
mutations in GyrA and lead to high-level fluoroquinolone resistance
[7]. MDR efflux pump is a membrane protein which can actively
extrude drugs, dyes, disinfectants and detergents by the force of ATP
hydrolysis or proton anti-direction movement. In the genome of S.
enterica serovar Typhimurium, five of nine known MDR efflux pumps
(AcrAB, MdtK, AcrEF, EmrB and MdfA) could extrude quinolones
when overexpressed [8]. Most recently, active MDR efflux pump has
been recognized as a primary fluoroquinolone resistant mechanism in
clinical S. enterica serovar Typhimurium [9,10].
Multiple efflux pumps in a single bacterial cell are often
expressed under precise and elaborate transcriptional control. In S.
enterica serovar Typhimurium, the regulators RamA, SoxS, MarA
and AcrR have been reported to participate in the regulation of
the expression of MDR efflux pumps [11,12,13]. When RamA
was overexpressed in S. enterica serovar Typhimurium or E.coli, the
strain exhibited decreased susceptibility to multidrugs [14,15]. It
has been confirmed that RamA can bind to the upstream
promoter region of acrAB and tolC and increase the expression
level of the efflux [16]. Recent study found that ramR, located in
the upstream region of ramA, could repress the expression of ramA
by binding to 210 region of its promoter [17]. In clinical isolates
of MDR S. enterica serovar Typhimurium, amino acid mutations,
deletions and frame shift mutations were also found in RamR [18].
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tration that prevents the growth of first-step resistant mutants or
the minimal inhibitory concentration of the most resistant
organism present in the heterogeneous bacterial population when
tested against greater than or equal to10
10 CFU/mL [19]. The
MPC represents a threshold above which the selective prolifera-
tion of resistant mutants is expected to occur rarely. However, the
strategy is based on the use of antibiotic concentrations that
require bacteria to obtain two concurrent resistance mutations for
growth [20]. Likewise, the range of antimicrobial plasma
concentrations between the MIC and the MPC of wild bacterial
population is defined as the mutant selection window (MSW) in
which selective amplification of spontaneous drug-resistant
mutants is more pronounced [21]. The concept of the MPC and
MSW has been characterized in some main clinical pathogenic
bacteria [22–25]. Recently, the MPCs and MSWs of different
fluoroquinolones to clinical isolates of S. enterica serovar Typhi-
murium were reported [26–28].
Some reports demonstrated that active efflux pumps contribut-
ed in the development of ciprofloxacin resistance of S. enterica
serovars Typhimurium [7,29]. The regulator RamA played a
predominant role in the development of MDR S. enterica serovars
Typhimurium based on the fact that no MDR mutant was
obtained when a susceptible strain with inactivated RamA was
selected under the selection pressure of different drugs [30–31]. In
addition to that, the RND efflux pump AcrAB which is an
important efflux pump in MDR S. enterica serovars Typhimurium
was shown to be mainly regulated by RamA [32,33]. However, the
overexpression of single AcrAB in the wild-type S. enterica serovar
Typhimurium ATCC14028s lacking individual acrAB gene did not
lead to the mutant exhibiting resistance to quinolones[8]. On the
basis of the three-dimensional structure of AcrB, it captured the
substrates from the periplasm or the outer leaflet of the
cytoplasmic membrane [34,35]. This might indicate the contri-
bution of some single component efflux pumps in the fluoroquin-
olone resistance in S. enterica serovar Typhimurium. Furthermore,
no study clearly showed whether RamA could activate the
expression of some single component efflux pumps in S. enterica
serovar Typhimurium. Likewise, the effect of RamA on the MPC
value and MSW of S. enterica serovar Typhimurium to ciproflox-
acin has not been reported until today.
The aim of this study was to elucidate the role of ramA in the
development of ciprofloxacin resistance of Salmonella enterica
serovar Typhimurium CVCC541 (ST). Spontaneous mutants
were selected via several passages of S. enterica sreovar Typhimur-
ium CVCC541 susceptible strain (ST) on M-H agar with
increasing concentrations of ciprofloxacin. RamA was inactivated
in ST and its spontaneous mutants and then, overexpressed on a
recombinant plasmid. The MPCs and mutant frequencies of ST
and a spontaneous mutant to ciprofloxacin in the presence,
absence and overexpression of RamA were determined. Further-
more, the role of RamR, a repressor of RamA was also studied in a
spontaneous mutant.
Materials and Methods
Drugs and reagents
Ciprofloxacin, ofloxacin, norfloxacin, sarafloxacin, enrofloxa-
cin, chloramphenicol, and florfenicol were purchased from
National Institute for the Control of Pharmaceutical and
Biological Products (Beijing, China). Ampicillin, kanamycin,
nalidixic acid, tetracycline, trypton and yeast extract were the
products of Bio Basic Inc (BBI, America). Tetracycline and
chloramphenicol, the better substrates for AcrAB [36] were used
for determining MICs of Salmonella enterica serovar Typhimurium
(CVCC 541) and the spontaneous mutants.
Unless otherwise indicated, the concentrations of ampicillin and
kanamycin used in the present study were 80 and 50 mg/L,
respectively.
Bacterial strain and plasmids
Salmonella enterica serovar Typhimurium (CVCC 541), a clinical
susceptible isolate from chicken in Changchun province in China
was supplied by China Institute of Veterinary Drug Control
(Beijing, China) and designed as ST in this report. The helper
plasmids pKD46 and pKD4 were purchased from E.coli Genetic
Stock Center in Yale University (New Haven, USA).
Antimicrobial susceptibility testing
The susceptibility of ST and the selected mutants were tested
using the two-fold broth microdilution method according to the
CLSI guidance [37]. MIC values of all strains were determined on
three independent occasions. Escherichia coli ATCC 25922 was used
as the quality control in all the susceptibility tests.
Selection of spontaneous mutants in vitro
Selection of spontaneous mutants with ciprofloxacin was
performed as previously described with some modifications [38].
Briefly, ST was cultured in Luria-Bertani (LB) broth at 37uC
overnight with vigorous shaking. 100 mL of the inoculum
(10
9 CFU/mL) was innoculated on MHA plates with increasing
concentrations of ciprofloxacin (16MIC, 26MIC, 46MIC,
86MIC) and incubated for 24 to 48 h at 37uC. A single colony
was selected from every selecting plate and incubated in LB broth
containing the same concentration of the drug as that in the plate.
The overnight culture of the colony from the selecting plate
containing the highest concentration of ciprofloxacin was spread
onto MHA plate supplemented with an increased concentration of
ciprofloxacin. The selection procedure was repeated for the strains
exhibiting high MIC of ciprofloxacin. The selected mutants in
every procedure were passed 10 times in LB broth without
antibiotics. MIC values of quinolones, tetracycline, chloramphen-
icol and florfenicol were examined and the selected mutants were
stored in glycerol at 280uC until used.
Amplification and Sequencing of the QRDRs
Genomic DNA from ST and the selected spontaneous mutants
were extracted from overnight cultures in LB broth at 37uC by using
the bacteria genomic DNA Mini extraction kit (Shanghai Generay
Biotech Co. Ltd, China). The QRDRs of gyrA, gyrB, parC and parE
were amplified using the primers (Table 1). The purified PCR
products weresequencedat commercial company(ShanghaiSangon
Biological Engineering Technology & Services Co. Ltd, China).
Accumulation of ciprofloxacin
Accumulation of ciprofloxacin in ST and its spontaneous
mutants in the presence or absence of CCCP (carbonyl cyanide-m-
chlorophenylhydrazone, which dissipates the proton motive force
and hence acts as an inhibitor of active efflux) or PAbN
(Phenylalanine arginine beta-naphthylamide, which is a compet-
itive inhibitor of resistance-nodulation-cell division [RND] pumps
of gram-negative bacteria) was determined by a modified
fluorometric method as previously described [9]. Fluorescence
was measured with Infinite
TM 200 microplate readers (TECAN
Group Ltd., Austria) at excitation and emission wavelengths of 276
and 452 nm for ciprofloxacin, respectively. The amount of
ciprofloxacin accumulated was calculated by comparison with a
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hydrochloride (pH 3.0). Results were expressed as nanograms of
ciprofloxacin incorporated per milligram (dry weight) of bacteria.
All experiments were performed at least three times to ensure
reproducibility. The mean and standard error was calculated.
Examination of the expression levels of MDR efflux
pumps
Total RNA from ST and its spontaneous mutants was harvested
from 2 mL aliquots of culture using RNAprep pure Cell/Bacteria
kit (TianGen BioTech Co. Ltd, China) according to the
manufacturer’s recommendation. DNA in total RNA was digested
by RNase-free DNase (Promega, America). PCR amplification
with the primers 16sF and 16sR (Table 1) was performed to
confirm the complete DNA digestion. OD260/280 values of total
RNA were detected using an Agilent 8451 UV-Visible spectro-
photometer (Agilent Technologies, Palo Alto, USA).
Reverse transcription-PCR (RT-PCR) was performed using
Superscript III reverse transcriptase (Invitrogen, America) accord-
ing to the method described in the manufacturer. The synthesized
cDNA was confirmed by PCR and stored at 220uC until
used. Real-time PCR was performed using the IQ5 multicolour
Table 1. Primers used in this study.
Primer Primer sequence (59-39) Product size (bp) Reference
Primers used to inactivating the genes and verifying the mutants
LRAF ACA CGA TTG TCG AGT GGA TTG ATG ATA ATT TGA ATC AGC 17
CGT TAC GTG TAG GCT GGA GCT GCT TC
LRAR ACG ATA AGC GCC TGG CGG CAGGTTGAACGTGCG GGT AAA 17
AAT GCG CAT ATG AAT ATC CTC CTT AG 1567
RAF GAG CAC GAT GAC CAT TTC CG
RAR CCT GTC ATT CGC TTT ATC TGG 1679 this study
Primers used to testing target sites mutation
GyrAF CTA TCT GGA TTA TGC GAT GTC TGT C
GyrAR GAA CCG AAG TTA CCC TGA CCA T 273 this study
GyrBF TGA ACG AAC TGC TGA GCG AAT A
GyrBR ATG GCT GGG CAA TGT AAA CG 540 this study
ParCF TGG AAA ACG CCT ACT TAA ACT ACT C
ParCR GTA TTT GGA CAG GCG GGA TT 344 this study
ParEF GTA CCG AGC TGT TCC TTG TG
ParER CCT TTC TTA CGC TTC AGT TGT T 436 this study
Primers used to real time RT-PCR
16sF GGT GTA GCG GTG AAA TGC GTA G
16sR CCA GGG CAC AAC CTC CAA GT 163 this study
AcrAF AAA ACG GCA AAG CGA AGG TC
AcrAR ATG CGG GTT AGG GAA GAT GG 140 this study
MdtKF CGT CGG CAT TTG TAT GGC TGT
MdtKR CAC GAC CTC AGG GTT GTC ATT G 94 this study
Primers used to amply the sequences of the regulatory loci
RAPF CCT TGA CGG CGT ATC TTT GC
RAPR GTC AAC GTG CGG GTA AAA ATG 495 this study
RARF TGG CAG CCC TTG ATT ATG AG
RARR AGT GTT CGG TAA AAG GCA GTT C 797 this study
MARF CTC CTA CCC ATC AGC GTT TCA
MARR ACA GGG CAG CAG CAT CAC AT 1236 this study
SOXSF GCC GTT GGT TAC CGC TAT TA
SOXSR CGT TCA GTA TTG TCA GGG ATG G 660 this study
SOXRF TAC ATA GCC CAG GTC CAT C
SOXRR TCG CTT ACA CTT ACA GTA TCA AC 983 this study
Primers used to the overexpression of RamA and RamR
ERAF GCG GGA TCC ATG ACC ATT TC
ERAR TTC TCG AGT CGC TTT ATC TGG C 402 this study
ERRF TGG GAT CCC TTG ATT ATG AG
ERRR AGT CTC GAG TAA AAG GCA GTT C 797 this study
doi:10.1371/journal.pone.0023471.t001
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primer pairs (Table 1), cDNA template and iQ SYBR Green
Supermix (TakaRa Biotechnology Co. Ltd, Japan). PCR ampli-
fication was conducted with an initial step of 30 s at 95uC,
followed by 35 cycles of 5 s at 95uC, 10 s at the annealing
temperature (59uC for 16sRNA, mdtK for 61uC and acrA for 55uC)
and 20 s at 72uC. To precisely test the relative expression level of
the interesting genes, the standard curves of the amplification of
16sRNA, mdtK and acrA were individually established. CT values
tested came within the linearity range for PCR amplification. Each
sample was run at least twice independently. The 2
2D (D Ct)
method was used to calculate increased fold of the gene tested in
the mutants compared to that in ST.
Inactivation and overexpression of the global regulator
RamA
The ramA was inactivated in ST as previously described [39].
Briefly, kanamycin resistance gene aph flanked by FRT (FLP
Recognition Target) sites was amplified by PCR under standard
conditions using the template plasmid pKD4 and hybrid primers.
These hybrid primers (Table 1) consisted of 20 nucleotides (nt) of
the helper plasmid pKD4 and 45 nt on the 59 and 39 ends of the
corresponding inactivated gene. The long PCR fragment
(1567 bp) was purified, digested with DpnI, repurified and
transferred into ST by electroporation, in which the Red
recombinase expression plasmid pKD46 was previously trans-
formed. Transformants were selected on LB agar containing
25 mg/L of kanamycin at 37uC. The inserted sequence was
amplified from intermediate kanamycin-resistant strain by using
the primers which located outside of inactivated gene. The
amplified PCR products were purified and sequenced. The
mutant ST (ramA::aph) was designated as SR in this report.
The deletions were then transferred to the spontaneous mutants
by P22HT105/int transductions as previously described [40]. The
mutants SI1(ramA::aph), SI2(ramA::aph) and SI3(ramA::aph) were
designated as SI1R, SI2R and SI3R, respectively.
The RamA was then compensated on a recombinant plasmid
pGEXW(gst-ramA). Briefly, the recombinant plasmid pGEXW(gst-
ramA) constructed with the vector pGEX-6p-1 and the sequence of
ramA from ST was transformed into SR and SI2R by
electroporation. The SR and SI2R strains harboring the
recombinant plasmid pGEXW(gst-ramA) was designated as STRA
and SI2RA, respectively. After the induction by IPTG, MICs of
STRA and SI2RA to different antimicrobial agents and the
expression level of acrA and mdtK in STRA were tested according
to the above-mentioned methods.
Amplification of the promoter regions of MDR efflux
pumps and the sequence of regulators
The promoter regions of MDR efflux pumps (AcrAB and
MdtK) and the sequences of the regulatory loci RamRA, MarRA,
SoxRS and AcrR were amplified and sequenced. Sequence
analysis was held using the following programs: BLAST (http://
blast.ncbi.nlm.nih.gov/Blast.cgi) and the software DNAStar
(DNASTAR Inc., Madison, WI).
Compensation of RamR in SI1
The recombinant plasmid pEThis::ramR was constructed from
pET-28a vector and the sequence containing wild-type ramR from
ST and transformed into SI1 by electroporation. The mutant
harboring the recombinant plasmid pEThis::ramR was designated as
SI1RR. After the induction by IPTG, MICs of SI1RR to various
antimicrobial agents were also determined as previously described.
Growth curves of ST and SR
A single colony of ST or SR was cultured in 10 mL of Luria-
Bertani (LB) liquid medium at 37uC without shaking for 24 h.
OD600 values of the cultures were detected using an Agilent 8451
UV-Visible spectrophotometer (Agilent Technologies, Palo Alto,
USA).The volume was adjusted slightly to give the same optical
density at 600 nm for both strains. The adjusted culture was
diluted 1:1000 into 300 mL of the same medium. 11 test tubes
with 10 mL each from this culture medium were prepared and
incubated at 37uC without shaking. Then 6 h later, a test tube was
withdrawn and used to test the cells density of the cell culture at
600 nm. After that, a test tube was withdrawn every 3h, and the
cell densities were monitored at OD600. Because the light
scattering was not proportional to cell density above an
OD600.1 at high cell densities, the OD600 was determined for a
1:10 dilution of the cultures. The growth curves of two strains were
plotted in Microsoft Excel.
MPCs and mutant frequencies of ciprofloxacin
For examination of the MPCs, the selected strains were
individually grown overnight at 37uC with the vigorous shaking.
Each overnight culture was diluted 1:100 into 20 mL of its
corresponding liquid medium for another subculturing at the same
condition. For the strain harboring the recombinant plasmid
pGEXW(gst-ramA), when OD600 values of cell culture attained to
0.6, IPTG at a final concentration of 0.2 mM was added. After the
culture for 8 h, all strains were centrifuged and concentrated by
resuspending in 2 mL LB broth. 200 uL concentrated cell culture
(approximately 10
10 CFU) was plated on MH agar plates
containing different concentrations of ciprofloxacin. Additionally,
the inocula from each strain were plated onto antibiotic-free plates
to obtain the precise number of CFU/mL. The antibiotic-
containing plates were incubated at 37uC for 72 h, and the
antibiotic-free plates were incubated under the same conditions for
24 h. Colony counts were conducted after 72 h incubation. The
mutational frequencies of the strains tested to ciprofloxacin were
calculated as the ratio of colonies grown on antibiotic-containing
plates to colonies formed on antibiotic-free plates [27]. The MPC
for each drug-isolate combination was defined as the lowest
fluoroquinolone concentration that prevented growth of resistant
mutants [21]. All MPC determinations were performed in
duplicate. The MPC/MIC ratio was determined by dividing the
MPC values by the MIC values.
Results
Resistant phenotype and target site mutations of
spontaneous mutants
During stepwise selection with ciprofloxacin, four spontaneous
mutants (SI1, SI2, SI3 and SI4) exhibiting decreased susceptibility
to ciprofloxacin were obtained. Table 2 showed that SI1 without
any target site mutations in its QRDRs exhibited decreased
susceptibility to chloramphenicol, florfenicol, tetracycline as well
as to quinolones. The target site mutation Ser83RPhe in the
QRDR of GyrA in SI2 led to high-level resistance to nalidixic acid
and decreased susceptibility to fluoroquinolones. SI3 harbored the
same target site mutation as that in SI2. However, it exhibited
fluoroquinolone resistance and showed significantly increase in the
MICs of chloramphenicol, florfenicol, tetracycline compared to
that of SI2. On the other hand, the MICs of SI4 to
fluoroquinolones were higher than that of SI3. The second target
mutation (Ala468RGlu) in QRDR of GyrB in SI4 might increase
the resistance of the mutant to the tested fluoroquinolones.
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ciprofloxacin accumulated in SI1 and SI3 compared to
that in ST
The spontaneous mutants SI1 without any target site mutation
in its QRDRs and SI3 harboring the Ser83RPhe mutation in the
QRDR of GyrA exhibited decreased susceptibility and high
resistance to the tested drugs, respectively. Therefore, the
concentrations of ciprofloxacin accumulated in the two strains
compared to that in ST in the presence and absence of CCCP or
PAbN were tested. The amounts of ciprofloxacin accumulated in
SI1 and SI3 appeared to be lower than that in ST in the absence
of efflux pump inhibiters (Figure 1). After CCCP was added, the
amounts of the drug accumulated in SI1 slightly increased
(approximately 1.15-fold), whereas lower than that in ST in the
absence of CCCP [Figure 1(A)]. When CCCP was added into the
incubation system containing SI3, the amount of ciprofloxacin
accumulated in SI3 dramatically increased and was near to that in
ST in the presence of CCCP [Figure 1(C)]. After the addition of
PAbN, the accumulation of ciprofloxacin in SI1 increased and was
near to that in ST in the presence of PAbN [Figure 1(B)].
Nevertheless, the concentration of ciprofloxacin accumulated in
SI3 in the presence of PAbN was near to that in ST, whereas lower
than that in ST in the presence of PAbN [Figure 1(D)].
Role of RamA in the susceptibility of SI1to the tested
drugs
In order to elucidate the role of RamA, the ramA in ST and SI1
was inactivated. Table 2 showed that the susceptibility of the SR
(STramA::aph) strain to the tested drugs did not dramatically
change compared to that of the ST. However, the MICs of SI1R
(SI1ramA::aph) to the tested drugs except for nalidixic acid
decreased 2- to 8-fold compared to that of SI1. The MICs of
SI1R to ciprofloxacin, sarafloxacin, enrofloxacin and nalidixic
acid were the same as that of SR. On the other hand, when RamA
was overexpressed in SR, MICs of STRA to the tested drugs
increased 2- to 6-fold compared to that of SR (Table 2). The MICs
of STRA to ofloxacin and tetracycline were the same as that of
SI1. The MICs of STRA to nalidixic acid was higher than that of
SI1. The MICs of STRA (SR with the overproduction of RamA)
to the remaining antimicrobial agents did not significantly change
except that the MICs of STRA to ciprofloxacin, norfloxacin and
enrofloxacin exhibited 2-fold decrease compared to that of SI1.
Likewise, the results of real-time RT-PCR showed that the
expression level of acrA and mdtK in SI1 and SI3 increased 6.08-,
3.87-fold and 30.1-, 8.15-fold, respectively, compared to that in
ST. The expression level of acrA in STRA was similar to that in
SI3 and MdtK expression in STRA was similar to SI1 (Table 2).
As a result, RamA was the main factor that controlled the
susceptibility of SI1 to ciprofloxacin by activating MdtK as well as
increasing the expression level of AcrAB.
Role of RamA in the susceptibility of SI3 to the tested
drugs
When RamA was inactivated in SI3, MICs of SI3R (SI3r-
amA::aph) to the tested drugs except for nalidixic acid exhibited 2-
to 8-fold decrease compared to that of SI3. The MICs of SI3R to
ciprofloxacin decreased 8-fold (CIP: SI3, 16 mg/L; SI3R, 2 mg/
L), which indicated that RamA played a predominant role in the
ciprofloxacin resistance of SI3. However, the SI3R strain still
exhibited resistance to the tested fluoroquinolones. In order to
further elucidate the contribution of single RamA to the
ciprofloxacin resistance of SI3, RamA was overexpressed in
SI2R (SI2ramA::aph). Table 2 showed that the SI2R and SI2 strains
had similar susceptibility to the tested drugs. When RamA was
overexpressed in SI2R, the MICs of SI2RA to ciprofloxacin,
norfloxacin, tetracycline and chloramphenicol increased 2-to16-
fold compared to that of SI2R. The susceptibility of SI2RA to
ofloxacin, sarafloxacin, and florfenicol was similar to that of SI2R.
Unexpectedly, the susceptibility of SI2RA to enrofloxacin and
nalidixic acid both exhibited reduced MICs compared to that of
SI2R. To be noticed, the MICs of SI2RA to ciprofloxacin
was lower than that of SI3R. The above-mentioned results
Table 2. The susceptibility to antibiotics, the relative expression level of MDR efflux pumps and target sites mutations of the
spontaneous mutants.
Strains Antibiotic agents MICs (mg/L) Target sites mutations Fold change of the gene expression
CIP NOR OFX SAR ENR NAL TET CHL FLO GyrA 83 GyrB 468 acrA mdtK
ST 0.0125 0.03 0.05 0.03 0.04 6.25 6.25 3.13 3.13 No No 1 1
SI1 0.1 0.4 0.4 0.2 0.4 10.42 12.5 10.42 12.5 No No 6.0862.44 3.8760.78
SI2 0.4 0.8 1.6 1.4 0.8 .500 7.81 5.47 5.47 SerRPhe No
SI3 16 53.33 32 26.67 21.33 ND 50 50 50 SerRPhe No 30.166.87 8.1561.77
SI4 32 64 53.33 64 42.67 ND 33.33 50 50 SerRPhe AlaRGlu
SR 0.0125 0.05 0.08 0.05 0.05 6.25 5.21 2.08 4.17
SI1R 0.0125 0.1 0.2 0.05 0.05 6.25 3.1 3.1 6.25
SI2R 0.3 0.8 1.6 1.3 0.8 .500 6.25 3.13 3.91 SerRPhe
SI3R 2 16 8 10.67 5.33 .500 6.25 6.25 8.33 SerRPhe
STRA 0.05 0.2 0.4 0.13 0.2 25 12.5 12.5 16.67 30.167.12 3.9260.39
SI2RA 0.8 3.2 1.6 1.07 0.2 31 25 50 3.13 SerRPhe
SI1RR 0.025 0.2 0.2 0.1 0.1 12.5 6.25 6.25 12.5
Notes: CIP, ciprofloxacin; NOR, norfloxacin; OFX, ofloxacin; SAR, sarafloxacin; ENR, enrofloxacin; NAL, nalidixic acid; TET, tetracycline; CHL, chloramphenicol; FLO,
florfenicol; ND, not tested; No, no mutatation; ST, Salmonella Typhimurium (CVCC541); SI1-SI4, the spontaneous mutants derived from ST under the selection pressure of
ciprofloxacin; SR, SI1R, SI2R and SI3R, the mutant of ST, SI1, SI2 and SI3 with inactivated ramA, respectively; STRA and SI2RA, SR and SI1R with the overproduction of
RamA, respectively; SI1RR, SI1 with the overproduction of RamR.
doi:10.1371/journal.pone.0023471.t002
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RamA contributed in the ciprofloxacin resistance of SI3.
Tetracycline and chloramphenicol were the good substrates of
AcrAB-TolC [36]. When RamA was inactivated in SI3, the
susceptibility of SI3R to tetracycline was the same as that of ST.
When RamA was overexpressed in SI2R, the MICs of SI2RA to
chloramphenicol was the same as that of SI3. Likewise, the
expression level of acrA in SI3 was similar to that in STRA with the
overproduction of RamA. These results indicated that the
expression of RamA was mainly responsible for increasing the
expression level of acrAB in SI3.
Role of RamR in the susceptibility of SI1 to the tested
drugs
The promoter regions of acrAB and mdtK in SI1 and SI3 were
the same as that in ST (primers not shown in Table 1). No
mutation was found in the sequence of regulatory loci MarRA,
SoxRS and AcrR from SI1 and SI3. Likewise, the promoter region
and open reading frame (ORF) of ramA in ST, SI1 and SI3 was the
same. However, a nucleotide mutation (G499A) and a nucleotide
deletion (C500) in the ORF of ramR from SI1 and SI3 were
observed (the number of the nucleotide position starts from the
initiation codon GTG).The nucleotide deletion led to the pro-
formation of stop codon (TGA) at the position 562.
Whether the changes in RamR contributed in ciprofloxacin
resistance by increasingthe expression level oframA,the complement
of RamR was conducted in SI1. Table 2 showed the decreased
susceptibility of SI1RR to the tested drugs except for nalidixic acid
and florfenicol compared to that of SI1. The MICs of SI1RR to
tetracycline reverted to that of ST. Although the MICs of SI1RR to
thetestedfluoroquinolonesdecreased2-to4-foldcompared tothatof
SI1, the susceptibility of SI1RR did not revert to that of ST.
Effect of RamA on the growth characteristic of ST
The growth speed of ST and SR did not vary during the culture
period of the first 12 h (Figure 2). When the two strains entered
into the logarithmic phase, the growth speed of SR was
significantly higher than that of ST. The SR strain entered into
the steady state phase after culturing for 30 h. However the ST
strain attained the steady state phase after culturing for 36 h. The
number of the bacteria in the initial and the steady state phase of
both strains were confirmed by plating serial dilutions in MH agar
without drugs. The initial concentration of both strains was
10
5 CFU/mL. While when they reached the steady state phase,
the concentration of the strains was 10
9 CFU/mL.
Effect of RamA on the MPC of ciprofloxacin
To elucidate the effect of RamA on the MPCs of the ST and SI2
strains to ciprofloxacin, the MPCs and mutant frequencies of
ciprofloxacin against ST and SI2 in the presence, absence and
overexpression of RamA were tested. Table 3 showed that the MPC of
SR to ciprofloxacin was the same as that of ST. The MPCs of STRA to
ciprofloxacin increased 5-fold compared to that of SR. Likewise, the
MPCs of SI2R to ciprofloxacin decreased 3-fold compared to that of
SI2 and its MSW became narrower. The overexpression of RamA in
SI2R strain resulted in increased MPC 4-fold to ciprofloxacin.
Figure 1. Accumulations of ciprofloxacin in the strains. Ciprofloxacin (10 mg/L) was added to each bacterial suspension at time zero; CCCP
(100 mM) or PAbN (80 mg/l) was added at 10 min as indicated by the arrow; The SI (CIP MICs, 0.1 mg/L) and SI3 (CIP MICs, 16 mg/L) strains were the
spontaneous mutants from ST under the selection pressure of ciprofloxacin; Each experiment represents the mean 6 standard error of the mean of
three separate experiments.
doi:10.1371/journal.pone.0023471.g001
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ciprofloxacin, the mutant frequencies of the STRA and SI2RA
strains with the overproduction of RamA all significantly
augmented compared to that of the ST and SI2 strains,
respectively (Figure 3). While the mutant frequencies of SI2R
strain were lower than that of SI2 strain. Likewise, it was obvious
that the overexpression of RamA promoted the development of
ciprofloxacin resistant mutants from ST and SI2.
Discussion
In this study, the two spontaneous mutants (SI1 and SI3) were
selectedfroma susceptible strainof S.enterica serovars Typhimurium
under the selection pressure of ciprofloxacin. The SI1 and SI3
strains were selected for further analysis since they demonstrated
different resistance genotype to the tested drugs. The SI1 strain
showed no target mutation in its QRDRs but exhibited decreased
susceptibility to the tested drugs compared to the ST strain. On the
other hand, although the SI3 strain demonstrated the same target
site mutationasthatofthe SI2strain,butitexhibitedhighresistance
to fluoroquinolones as well as to tetracycline and chloramphenicol.
Our study demonstrated that RamA was the main factor that
controlled the susceptibility of SI1 to ciprofloxacin by activating
MdtK as well as increasing the expression level of AcrAB. Likewise,
the accumulation experiment in SI1 indicated that at least an efflux
pump independent on the electrochemical potential of H
+ might
exist and its efflux to ciprofloxacin depended on the RND efflux
pump. It had been confirmed that AcrAB-TolC, a predominant
efflux pump in the RND family depended on the electrochemical
potential of H
+ and it captured the substrates from the periplasm or
the outer leaflet of the cytoplasmic membrane [41,34–35]. While
the MDR efflux pump MdtK belonged to the MATE family which
mainly depended on the electrochemical potential of Na
+ [42].
Recent report demonstrated that MdtK extruded fluoroquinolones
into periplasmic space [43]. This study results indicated that the
cooperation of AcrAB and MdtK might contribute to the efflux of
ciprofloxacinin SI1. Interestingly, inE.coli, thehigh-level expression
of ydhE (MATE family member) allowed the strain to grow on
otherwise lethal concentrations of the fluoroquinolone norfloxacin
and the cooperation of YdhE and AcrAB led to a synergic increase
in fluoroquinolone resistance [44].
The second spontaneous mutant SI3 (CIP MICs, 16 mg/L)
harboring a Ser83RPhe mutation in the QRDR of GyrA
exhibited MDR. The result of ciprofloxacin accumulated in SI3
indicated the presence of at least another efflux pump that not
belonging to the RND family but inhibited by CCCP. Genomic
analyses revealed that Salmonella Typhimurium LT2 had five
putativeRNDtransportersystems,fourteenputativeMFtransporter
systems,two putativeMATEtransporterssystemsandthreeputative
ABC transporter systems (http://www.membranetransport.org).
Among them, the members of RND, MF and MATE transporter
systems could extrude quinolones when overexpressed in vitro [8]. It
was reported that the member of MF family depended on the
electrochemical potential of H
+ and could extrude its substrate into
periplasmic space or outer niche with the help of TolC [42,43].
Therefore, the members in the MF family might contribute in the
ciprofloxacin resistance in SI3.
AcrAB is a predominant MDR efflux pump in S. enterica serovars
Typhimurium. Ricci et al. demonstrated that when AcrB was
inactivated in a susceptible S. enterica serovars Typhimurium, the
ciprofloxacin resistant mutants were very difficulty to be selected.
When TolC was inactivated, no ciprofloxacin resistant mutant was
selected [30]. Therefore, AcrAB was the main channel by which
ciprofloxacin in the cell extrude directly into outer niche. In this
study, the expression of RamA was mainly responsible for
increasing the expression level of acrAB, which was corresponded
to the previously published results [33,45]. However, the
expression level of mdtK in SI3 was higher than that in SI1 and
STRA. The members of MF family might also contribute in the
ciprofloxacin-resistance in SI3. These efflux pumps might extrude
ciprofloxacin mainly into periplasmic space and then, AcrAB
directly extrude the drug into outer niche. The synergetic
transportation mechanism between AcrAB and other single
component efflux pumps had been confirmed in E.coli [46,47].
Likewise, our results also indicated that the synergetic transpor-
tation mechanism might exist in SI3. For instance, when RamA
was overexpressed in SR or SI2R, the strains did not produce
resistance to ciprofloxacin. When RamA was inactivated in SI3,
the MICs of SI3R to ciprofloxacin dramatically decreased,
whereas still higher than the resistant breakpoint described in
CLSI [37]. On the other hand, the selected spontaneous mutants
Figure 2. Growth curves of ST and SR (STramA::aph).
doi:10.1371/journal.pone.0023471.g002
Table 3. Mutant prevention concentration (MPC) of ciprofloxacin against the ST and SI2 strains in the presence, absence and
overexpression of RamA.
Strains Genotype MIC (mg/l) MPC (mg/l) MPC/MIC
ST wild-type 0.0125 0.3 24
SR ST ramA::aph 0.0125 0.3 24
STRA SR pGEXW(gst-ramA) +IPTG 0.05 1.5 30
SI2 Ser83RPhe in GyrA 0.4 6 15
SI2R ramA::aph+Ser83RPhe in GyrA 0.3 2 7
SI2RA SI2R pGEXW(gst-ramA) +IPTG 0.8 8 10
Notes: CIP, ciprofloxacin; ENR, enrofloxacin.
doi:10.1371/journal.pone.0023471.t003
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concentrations of ciprofloxacin exhibited decreased susceptibility
to ciprofloxacin, whereas the same susceptibility to tetracycline
and chloramphenicol as that in ST (unpublished data). As a result,
the expression of RamA promoted the development of ciproflox-
acin resistance by activating MdtK and increasing the expression
level of acrAB in S. enterica serovars Typhimurium. Likewise, when
MarA, another regulator of MDR efflux pumps was inactivated in
SI1 and SI3, the susceptibility of the mutants to the drugs tested
did not dramatically change (data not shown).
MPC and MSW focus on the development of resistant mutants in
susceptible bacterial population. Since spontaneous mutants with a
site mutation in gene usually arise at a frequency of about 10
26 to
10
28, the first-exposure to sub-lethal concentrations of fluoroquin-
olones screens mutants with a single target site mutation [48,49]. In
clinical practice, the presence of the first-step mutants in the
bacterial population prior to fluoroquinolnes treatment may be the
primary cause leading to therapeutic failure by the enrichment and
amplification during therapy. In this study, the spontaneous
mutants SI1 and SI2 were the first-step mutants from ST (the SI1
and SI2 strains were selected on 16MIC and 86MIC selecting
plate, respectively). The results of MPC showed that the SI2RA
strain with the overproduction of RamA had the highest MPCs
among six strains tested and the MPC of SI2 was higher than that of
STRA. Likewise, the mutant frequencies of SI2RA were higher
than that of SI2 under the same selection pressure of ciprofloxacin.
This indicated that the first-step mutants harboring a target site
mutation in the QRDR of GyrA in a susceptible S. enterica serovars
Typhimurium population were the main source for the develop-
ment of ciprofloxacin resistant mutants. The overexpression of
RamA promoted the development of ciprofloxacin resistant
mutants. To be noticed, the MPC, MSW and mutant frequencies
of the SI2R (SI2ramA::aph) strain to ciprofloxacin was all lower than
that of SI2. Therefore, the inhibition of the expression level of ramA
in S. enterica serovar Typhimurium could decrease the appearance of
the second-step resistant mutants to ciprofloxacin.
RamR, a member of the TetR family is a local repressor of
RamA. Inactivation of RamR in a susceptible S. enterica serovars
Typhimurium strain exhibited decreased susceptibility to multi-
drugs due to the increased expression of AcrAB via the increased
expression of RamA. In contrast, the inactivation of RamA,
MarR, MarA, SoxR, and SoxS did not affect the susceptibilities of
the strain [17]. Likewise, RamR could directly bind to the
promoter region of ramA [50]. In this study, only mutations in ramR
were found in the spontaneous mutants SI1 and SI3. When RamR
was complemented in SI1, the MICs of SI1RR to fluoroquino-
lones decreased 2- to 4-fold compared to that of SI1, whereas were
still higher that of ST. This indicated that these mutations in ramR
participated in the ciprofloxacin resistance by increasing the
expression level of ramA. Likewise, RamA was still regulated by
other protein except for RamR in the development of ciproflox-
acin resistance of S. enterica serovars Typhimurium. Currently, the
changes of RamR were often found in clinical isolates of MDR S.
enterica serovars Typhimurium and considered as the main cause
leading to MDR of strain [18]. To the best of our knowledge, the
mutations in RamR presented in this study have not been reported
before (the nucleotide sequence of RamR found in the mutant SI1
has been assigned the accession number HQ114265 in the
GenBank nucleotide sequence database).
In conclusion, RamA was the main factor that controlled the
susceptibility of SI1 to ciprofloxacin by activating the MDR efflux
pump MdtK as well as increasing the expression level of acrAB.I n
SI3, the expression of RamA was responsible for increasing the
expression level of acrAB. In a susceptible S. enterica serovars
Typhimurium population, the first-step mutants harboring a target
site mutation in the QRDR of GyrA was the main source for the
development of ciprofloxacin resistant mutants. The expression of
RamA promoted the development of ciprofloxacin resistant
mutants. The inhibition of RamA could decrease the appearance
of the ciprofloxacin resistant mutants.
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